At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
ATB200 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
In Brief
A Phase 2 clinical trial evaluating ATB200 and AT2221 for Pompe Disease. Completed, enrolled 29 participants across 19 sites in 6 countries.
Detailed Summary
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPompe Disease
CountriesAustralia, Germany, Netherlands, New Zealand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartApr 2016
Primary CompletionAug 2024
TodayJul 2026
First PostedFeb 5, 2016
Enrollment StartApr 1, 2016
Primary CompletionAug 22, 2024
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 10.4 years ago
Interventions
ATB200drug
AT2221drug